Deutsch English Français

Contact

EP3172216

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP3172216

EP3172216 - 2,3'-ANHYDRO-2'-DÉOXY-5-FLUOROURIDINE DERIVATIVES WITH CYTOTOXIC ACTIVITY, A MANUFACTURING PROCESS AND USE THEREOF [Right-click to bookmark this link]
Former [2017/22]	2,3'-Anhydro-2'-deoxy-5-fluorouridine derivatives with cytotoxic activity, a manufacturing process and application
	[2018/10]
Status	No opposition filed within time limit Status updated on 16.08.2019 Database last updated on 16.07.2024
Former	The patent has been granted Status updated on 07.09.2018
Former	Grant of patent is intended Status updated on 02.08.2018
Former	Request for examination was made Status updated on 25.06.2018
Former	Grant of patent is intended Status updated on 08.03.2018
Former	Request for examination was made Status updated on 28.04.2017
Most recent event Tooltip	01.07.2022	Lapse of the patent in a contracting state New state(s): MK	published on 03.08.2022 [2022/31]
Applicant(s)	For all designated states Adam Mickiewicz University Wieniawskiego 1 61-712 Poznan / PL
	[2017/22]
Inventor(s)	01 / CELEWICZ, Lech os. Boleslawa Chrobrego 1 m. 62 PL-60-681 Poznan / PL
	02 / KACPRZAK, Karol Kozia 18 PL-62-053 Pecna / PL
	03 / LEWANDOWSKA, Marta Gierymskiego 70 PL-63-100 Srem / PL
	04 / RUSZKOWSKI, Piotr Tarninowa 3 PL-62-002 Suchy Las / PL
	[2017/22]
Representative(s)	Lisiecki, Wojciech ul. Wieniawskiego 1 61-712 Poznan / PL
	[2017/22]
Application number, filing date	14772458.7	22.08.2014
	[2017/22]
	WO2014PL50050
Priority number, date	PL20140408981	24.07.2014 Original published format: PL 40898114
	[2017/22]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2015050468
	Date:	09.04.2015
	Language:	EN
	[2015/14]
	Type:	A1 Application with search report
	No.:	EP3172216
	Date:	31.05.2017
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 09.04.2015 takes the place of the publication of the European patent application.
	[2017/22]
	Type:	B1 Patent specification
	No.:	EP3172216
	Date:	10.10.2018
	Language:	EN
	[2018/41]
Search report(s)	International search report - published on:	EP	09.04.2015
Classification	IPC:	C07F9/24, C07H19/073, A61K33/42, A61P35/00	[2017/22]
	CPC:	C07H19/10 (EP,US); A61K33/42 (EP,US); A61P35/00 (EP); C07F9/24 (EP,US); C07F9/6561 (EP,US); C07H19/073 (EP,US)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/22]
Extension states	BA	Not yet paid
	ME	Not yet paid
Title	German:	2,3'-ANHYDRO-2'-DEOXY-5-FLUORURIDIN-DERIVATE MIT ZYTOTOXISCHER AKTIVITÄT, HERSTELLUNGSVERFAHREN UND ANWENDUNG	[2017/22]
	English:	2,3'-ANHYDRO-2'-DÉOXY-5-FLUOROURIDINE DERIVATIVES WITH CYTOTOXIC ACTIVITY, A MANUFACTURING PROCESS AND USE THEREOF	[2018/10]
	French:	DÉRIVÉS DE 2,3'-ANHYDRO-2'-DÉSOXY-5-FLUOROURIDINE À ACTIVITÉ CYTOTOXIQUE, PROCÉDÉ DE FABRICATION ET APPLICATION	[2017/22]
	Former [2017/22]	2,3'-Anhydro-2'-deoxy-5-fluorouridine derivatives with cytotoxic activity, a manufacturing process and application
Entry into regional phase	21.01.2015	National basic fee paid
	21.01.2015	Designation fee(s) paid
	21.01.2015	Examination fee paid
Examination procedure	19.02.2015	Examination requested [2017/22]
	19.02.2015	Date on which the examining division has become responsible
	16.06.2017	Amendment by applicant (claims and/or description)
	09.03.2018	Communication of intention to grant the patent
	08.06.2018	Fee for grant paid
	08.06.2018	Fee for publishing/printing paid
	19.06.2018	Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
	03.08.2018	Communication of intention to grant the patent
	14.08.2018	Receipt of the translation of the claim(s)
Opposition(s)	11.07.2019	No opposition filed within time limit [2019/38]
Fees paid	Renewal fee
	25.08.2016	Renewal fee patent year 03
	22.06.2017	Renewal fee patent year 04
	30.08.2018	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	22.08.2014
	AL	10.10.2018
	AT	10.10.2018
	CY	10.10.2018
	CZ	10.10.2018
	DK	10.10.2018
	EE	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	IT	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	MC	10.10.2018
	MK	10.10.2018
	MT	10.10.2018
	NL	10.10.2018
	RO	10.10.2018
	RS	10.10.2018
	SE	10.10.2018
	SI	10.10.2018
	SK	10.10.2018
	SM	10.10.2018
	TR	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
	PT	10.02.2019
	[2022/31]
Former [2021/34]	HU	22.08.2014
	AL	10.10.2018
	AT	10.10.2018
	CY	10.10.2018
	CZ	10.10.2018
	DK	10.10.2018
	EE	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	IT	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	MC	10.10.2018
	MT	10.10.2018
	NL	10.10.2018
	RO	10.10.2018
	RS	10.10.2018
	SE	10.10.2018
	SI	10.10.2018
	SK	10.10.2018
	SM	10.10.2018
	TR	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
	PT	10.02.2019
Former [2021/32]	HU	22.08.2014
	AL	10.10.2018
	AT	10.10.2018
	CY	10.10.2018
	CZ	10.10.2018
	DK	10.10.2018
	EE	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	IT	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	MC	10.10.2018
	NL	10.10.2018
	RO	10.10.2018
	RS	10.10.2018
	SE	10.10.2018
	SI	10.10.2018
	SK	10.10.2018
	SM	10.10.2018
	TR	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
	PT	10.02.2019
Former [2021/26]	AL	10.10.2018
	AT	10.10.2018
	CY	10.10.2018
	CZ	10.10.2018
	DK	10.10.2018
	EE	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	IT	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	MC	10.10.2018
	NL	10.10.2018
	RO	10.10.2018
	RS	10.10.2018
	SE	10.10.2018
	SI	10.10.2018
	SK	10.10.2018
	SM	10.10.2018
	TR	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
	PT	10.02.2019
Former [2020/25]	AL	10.10.2018
	AT	10.10.2018
	CZ	10.10.2018
	DK	10.10.2018
	EE	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	IT	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	MC	10.10.2018
	NL	10.10.2018
	RO	10.10.2018
	RS	10.10.2018
	SE	10.10.2018
	SI	10.10.2018
	SK	10.10.2018
	SM	10.10.2018
	TR	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
	PT	10.02.2019
Former [2020/17]	AL	10.10.2018
	AT	10.10.2018
	CZ	10.10.2018
	DK	10.10.2018
	EE	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	IT	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	NL	10.10.2018
	RO	10.10.2018
	RS	10.10.2018
	SE	10.10.2018
	SI	10.10.2018
	SK	10.10.2018
	SM	10.10.2018
	TR	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
	PT	10.02.2019
Former [2019/50]	AL	10.10.2018
	AT	10.10.2018
	CZ	10.10.2018
	DK	10.10.2018
	EE	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	IT	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	NL	10.10.2018
	RO	10.10.2018
	RS	10.10.2018
	SE	10.10.2018
	SI	10.10.2018
	SK	10.10.2018
	SM	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
	PT	10.02.2019
Former [2019/40]	AL	10.10.2018
	AT	10.10.2018
	CZ	10.10.2018
	DK	10.10.2018
	EE	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	IT	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	NL	10.10.2018
	RO	10.10.2018
	RS	10.10.2018
	SE	10.10.2018
	SK	10.10.2018
	SM	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
	PT	10.02.2019
Former [2019/37]	AL	10.10.2018
	AT	10.10.2018
	CZ	10.10.2018
	DK	10.10.2018
	EE	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	IT	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	NL	10.10.2018
	RO	10.10.2018
	RS	10.10.2018
	SE	10.10.2018
	SM	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
	PT	10.02.2019
Former [2019/35]	AL	10.10.2018
	AT	10.10.2018
	CZ	10.10.2018
	DK	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	IT	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	NL	10.10.2018
	RS	10.10.2018
	SE	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
	PT	10.02.2019
Former [2019/34]	AL	10.10.2018
	AT	10.10.2018
	DK	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	IT	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	NL	10.10.2018
	RS	10.10.2018
	SE	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
	PT	10.02.2019
Former [2019/26]	AL	10.10.2018
	AT	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	NL	10.10.2018
	RS	10.10.2018
	SE	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
	PT	10.02.2019
Former [2019/25]	AT	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	NL	10.10.2018
	RS	10.10.2018
	SE	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
Former [2019/24]	AT	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	NL	10.10.2018
	SE	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	GR	11.01.2019
	IS	10.02.2019
Former [2019/23]	AT	10.10.2018
	ES	10.10.2018
	FI	10.10.2018
	HR	10.10.2018
	LT	10.10.2018
	LV	10.10.2018
	NL	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	IS	10.02.2019
Former [2019/22]	FI	10.10.2018
	LT	10.10.2018
	NL	10.10.2018
	BG	10.01.2019
	NO	10.01.2019
	IS	10.02.2019
Former [2019/21]	FI	10.10.2018
	LT	10.10.2018
	NL	10.10.2018
	NO	10.01.2019
	IS	10.02.2019
Former [2019/20]	LT	10.10.2018
	NL	10.10.2018
	NO	10.01.2019
Former [2019/17]	NL	10.10.2018
Cited in	International search	[A]WO2012094248 (NANJING MOLECULAR RES INC [CN], et al) [A] 1-7;
		[A]WO2012117246 (NUCANA BIOMED LTD [GB], et al) [A] 1-7;
		[A] - LEWANDOWSKA MARTA ET AL, "Synthesis of 3'-azido-2',3'-dideoxy-5-fluorouridine phosphoramidates and evaluation of their anticancer activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, (20130701), vol. 67, doi:10.1016/J.EJMECH.2013.06.047, ISSN 0223-5234, pages 188 - 195, XP028710081 [A] 1-7 DOI: http://dx.doi.org/10.1016/j.ejmech.2013.06.047
		[AD] - NAVEEN C. SRIVASTAV ET AL, "Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (20101101), vol. 20, no. 22, doi:10.1016/j.bmcl.2010.08.120, ISSN 0960-894X, pages 6790 - 6793, XP055146737 [AD] 1-7 DOI: http://dx.doi.org/10.1016/j.bmcl.2010.08.120

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p